Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate.
about
Factor replacement for haemophilia--should cryoprecipitate be used?Is There Evidence for Neurocognitive Dysfunctions in Patients with Postnatal HIV Infection? A Review on the Cohort of Hemophilia PatientsHemophilia complications. Hepatitis C infection and its management.Choice of factor concentrates for haemophilia: a developing world perspective.Advances in the therapy of von Willebrand disease.Optimization of factor VIII replacement therapy: can structural studies help in evading antibody inhibitors?An economic model of haemophilia in Mexico.Safety and supply of haemophilia products: worldwide perspectives.von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements.A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.The early history of haemophilia treatment: a personal perspective.Guidelines for the management of hemophilia.Judith Graham Pool and the discovery of cryoprecipitate.Observations from Global Survey 2001: an emerging database for progress.
P2860
Q33785729-DEF6F966-C992-4D0E-ADBC-154EE0EB56DAQ33794596-40F7AC46-75FF-4C36-9F71-9DE20A8574F1Q34029520-7C2BCB1A-E2B6-4FF3-83E5-70B00162A8AFQ34117224-4B59DB71-87A3-4FF6-9BF6-3ECA4B32FA98Q34637009-C2F31999-96BF-4DAF-80AE-006700AF7F9AQ34983308-7C487039-9C04-4656-B94A-77CFBD858FD5Q35666758-DAA0249C-FB70-427D-B33E-C6241CDADDC0Q35824847-0E7C7860-6406-47CD-8213-CA4A489FB4D1Q37100261-0CF2D125-200F-41C5-AEAB-004896C19A36Q37894820-7AB2BDA1-0323-4791-8F73-4F0C1FDD0ACAQ45858880-9CDE6B9D-ED0B-4C73-BC49-EFAFE474B826Q45873216-D43ACAC2-DC25-4842-AF15-F6BF79268443Q45880345-0D474066-D7E4-4BD6-9D0F-9C65EAE5AA2BQ45882804-DA348992-0AA8-4B60-9280-586D2F5941D7Q45885147-6DDCAA20-3FB0-4314-AF05-E72743AE86EA
P2860
Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate.
@ast
Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate.
@en
type
label
Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate.
@ast
Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate.
@en
prefLabel
Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate.
@ast
Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate.
@en
P2093
P2860
P1433
P1476
Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2516.1999.00317.X
P577
1999-09-01T00:00:00Z